PharmacyCodes



Tiagabina [Inn-Spanish] en es it fr

Tiagabina [Inn-Spanish] Brand names, Tiagabina [Inn-Spanish] Analogs

Tiagabina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Tiagabina [Inn-Spanish] Chemical_Formula

C20H25NO2S2

Tiagabina [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic/gabitril.htm

Tiagabina [Inn-Spanish] fda sheet

Tiagabina_[Inn-Spanish] FDA

Tiagabina [Inn-Spanish] msds (material safety sheet)

Tiagabina [Inn-Spanish] Synthesis Reference

No information avaliable

Tiagabina [Inn-Spanish] Molecular Weight

375.55 g/mol

Tiagabina [Inn-Spanish] Melting Point

No information avaliable

Tiagabina [Inn-Spanish] H2O Solubility

No information avaliable

Tiagabina [Inn-Spanish] State

Solid

Tiagabina [Inn-Spanish] LogP

3.417

Tiagabina [Inn-Spanish] Dosage Forms

No information avaliable

Tiagabina [Inn-Spanish] Indication

For the treatment of partial seizures

Tiagabina [Inn-Spanish] Pharmacology

Tiagabine is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells.

Tiagabina [Inn-Spanish] Absorption

Tiagabine is nearly completely absorbed (>95%).

Tiagabina [Inn-Spanish] side effects and Toxicity

No information avaliable

Tiagabina [Inn-Spanish] Patient Information

No information avaliable

Tiagabina [Inn-Spanish] Organisms Affected

Humans and other mammals